Manufacturing Scale-Up Small scale-focused pharma with a pipeline across infectious diseases, autoimmune conditions, cachexia, and retinal diseases will likely require external contract manufacturing for process development, tech transfer, and fill finish as it advances toward clinical trials or initial commercialization.

Clinical Collaborations With multiple therapeutic areas and a public company profile, EOM could leverage CROs and regulatory services for IND/CTA submissions, PK PD studies, data management, and trial execution to accelerate development timelines.

Commercialization Partners To reach specialized patient populations in rheumatology, infectious disease, and ophthalmology, the company may seek distributor or co promotion partners and regional market access arrangements in the US and international markets.

Licensing Alliances First in class programs present licensing or co development opportunities for larger pharma, enabling milestone based funding, risk sharing, and pipeline expansion without large in house teams.

Strategic Outsourcing Given a lean headcount, EOM could benefit from outsourced regulatory, quality, IT, and commercialization support to accelerate go to market readiness and maintain GMP compliance as it scales.